Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH)

Medical Hypotheses

Volumn 65, Issue 2, 2005, Pages 377-379

  Yamagishi, S ^a   Nakamura, K ^a   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; TRIACYLGLYCEROL;

ARTICLE; BODY WEIGHT; DATA ANALYSIS; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOTHESIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; POSTPRANDIAL STATE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ACARBOSE; CLINICAL TRIALS; DIABETES COMPLICATIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPOLYSIS; LIVER; LIVER DISEASES; META-ANALYSIS; MODELS, THEORETICAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 19744379596     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.01.032     Document Type: Article

References (22)

1. A.J. Scheen Management of the metabolic syndrome Minerva Endocrinol 29 2004 31 45
2. J. Choudhury, and A.J. Sanyal Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease Clin Liver Dis 8 2004 575 594
3. E.M. Brunt Nonalcoholic steatohepatitis Semin Liver Dis 24 2004 3 20
4. A.J. Sanyal AGA technical review on nonalcoholic fatty liver disease Gastroenterology 123 2002 1705 1725
5. K.S. Kumar, and P.F. Malet Nonalcoholic fatty liver disease: a feature of the metabolic syndrome Mayo Clin Proc 75 2000 733 739
6. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2000 1221 1231
7. K.G. Tolman, V. Fonseca, M.H. Tan, and A. Dalpiaz Narrative review: hepatobiliary disease in type2 diabetes mellitus Ann Intern Med 141 2004 946 956
8. L.M. Grant, and M. Lisker-Melman Nonalcoholic fatty liver disease Ann Hepatol 3 2004 93 99
9. G. Boden Role of fatty acids in the pathogenesis of insulin resistance and NIDDM Diabetes 47 1997 3 10
10. S.A. Harrison, S. Kadakia, K.A. Lang, and S. Schenker Nonalcoholic steatohepatitis: what we know in the new millennium Am J Gastroenterol 97 2002 2714 2724
11. C.A. Matteoni, Z.M. Younossi, T. Grumlich, N. Boparai, Y.C. Liu, and A.J. McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419
12. W. Youssef, and A.J. McCullough Diabetes mellitus, obesity, and hepatic steatosis Semin Gastrointest Dis 13 2002 17 30
13. A. Propst, T. Propst, G. Judmaier, and W. Vogel Prognosis in nonalcoholic steatohepatitis Gastroenterology 108 1995 1607
14. P. Angulo, J.C. Keach, K.P. Batts, and K.D. Lindor Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 1999 1356 1362
15. J.B. Dixon, P.S. Bhathal, and P.E. O'Brien Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severe obese Gastroenterology 121 2001 91 100
16. R.J. Heine, and J.M. Dekker Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease Diabetologia 45 2002 461 475
17. P. Rosen, P.P. Nawroth, G. King, W. Moller, H.J. Tritschler, and L. Packer The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society Diabetes Metab Res Rev 17 2001 189 212
18. A. Ceriello, and E. Motz Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited Arteriscler Thromb Vasc Biol 24 2004 816 823
19. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso STOP-NIDDM trial research group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial Lancet 359 2002 2072 2077
20. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso STOP-NIDDM trial research group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial JAMA 290 2003 486 494
21. M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp Acarbose reduces the risk for myocardial infarction in type2 diabetic patients: meta-analysis of seven long-term studies Eur Heart J 25 2004 10 16
22. H.W.M. Breuer Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes Int J Clin Pharm Ther 41 2003 421 440